Rachael Alford, Chief Operating Officer of Yarrow Bioscience, Inc., filed a statement of changes in beneficial ownership on October 30, 2026, reporting the acquisition of a stock option covering 89,844 shares of common stock on October 29, 2026.

Key Highlights

  • Reporting person: Rachael Alford, Chief Operating Officer of Yarrow Bioscience, Inc. (NASDAQ:YARW)
  • Security awarded: A stock option (right to buy) covering 89,844 shares of common stock, acquired on October 29, 2026
  • Exercise price: $20 per share, with an expiration date of October 29, 2036
  • Vesting schedule: One quarter vests on July 28, 2027; the remaining three quarters vest in equal monthly installments over the following three years, subject to continued service
  • Post-transaction holdings: 89,844 derivative securities beneficially owned directly, with a price of $0 reported for the derivative security itself
  • Filing signed: By Tyler Zeronda, as attorney-in-fact for Rachael Alford, on October 30, 2026

Stock Option Grant Details for Yarrow Bioscience COO Rachael Alford

According to the filing, Yarrow Bioscience, Inc. granted its Chief Operating Officer, Rachael Alford, a stock option representing the right to purchase 89,844 shares of the company's common stock. The transaction date is reported as October 29, 2026, and the option carries an exercise price of $20 per share. The option is classified as a derivative security acquired directly by the reporting person, with a reported price of $0 for the derivative itself at the time of the grant.

The filing discloses that the option will expire on October 29, 2036, giving it a ten-year term from the grant date. Yarrow Bioscience, Inc. is identified in the filing as a bioscience company with its address listed at 470 James Street, Suite 007, New Haven, Connecticut 06513. The filing indicates this was submitted by one reporting person and is not an amendment to a prior filing.

The vesting schedule, as described in the filing's explanation of responses, calls for one quarter of the 89,844 shares to vest on July 28, 2027. The remaining three quarters are to vest "in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date," according to the filing. Following the reported transaction, the filing states that Alford directly and beneficially owns 89,844 derivative securities. No non-derivative securities transactions were reported in Table I of the filing.

What Was Disclosed

Yarrow Bioscience, Inc. Chief Operating Officer Rachael Alford reported the acquisition of a stock option to purchase 89,844 shares of common stock at $20 per share, granted on October 29, 2026, expiring October 29, 2036, with a multi-year vesting schedule tied to continued service.